Study on the Clinical Safe and Effective Methods of Arsenic-Containing Compound-Qinghuang Powder in the Treatment of Myelodysplastic Syndrome
Objective. To establish the clinical safe and effective methods of arsenic-containing compound-Qinghuang Powder (compound-QHP) in the treatment of myelodysplastic syndrome (MDS). Methods. 200 patients with MDS were treated with compound-QHP (daily dose of 0.1 g realgar). The blood arsenic concentrat...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2017-01-01
|
Series: | Evidence-Based Complementary and Alternative Medicine |
Online Access: | http://dx.doi.org/10.1155/2017/2095682 |
id |
doaj-f165d0dd6bda49e5a5cac00bac9f2604 |
---|---|
record_format |
Article |
spelling |
doaj-f165d0dd6bda49e5a5cac00bac9f26042020-11-24T23:38:02ZengHindawi LimitedEvidence-Based Complementary and Alternative Medicine1741-427X1741-42882017-01-01201710.1155/2017/20956822095682Study on the Clinical Safe and Effective Methods of Arsenic-Containing Compound-Qinghuang Powder in the Treatment of Myelodysplastic SyndromeQianzhe Zhu0Zhongyang Deng1Shirong Zhu2Pan Zhao3Mingjing Wang4Xiaomei Hu5Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, ChinaDepartment of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, ChinaDepartment of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, ChinaDepartment of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, ChinaDepartment of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, ChinaDepartment of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, ChinaObjective. To establish the clinical safe and effective methods of arsenic-containing compound-Qinghuang Powder (compound-QHP) in the treatment of myelodysplastic syndrome (MDS). Methods. 200 patients with MDS were treated with compound-QHP (daily dose of 0.1 g realgar). The blood arsenic concentrations (BACs) were detected by atomic fluorescence spectrophotometry (HF-AFS). After treatment for 1 month, the patients were randomly divided into group A and group B when the BACs were less than 20 μg/L. Daily dose of realgar was maintained in group A and it was increased to that when the BACs were more than 20 μg/L in group B. The BAC and clinical efficacy and safety in two groups were compared at the end of the treatment with compound-QHP. Results. The average BAC of group B was significantly higher than that of group A (P<0.01). The rates of hematology improvement and reduced transfusion were significantly higher in group B than in group A (P<0.05). The HGB, ANC, and PLT significantly increased in group B after treatment (P>0.05). Conclusions. Monitoring the BAC and adjusting the daily dose of realgar to increase the effective BAC and then improving efficacy without increasing the clinical toxicity are the clinical safe and effective methods in the treatment of MDS.http://dx.doi.org/10.1155/2017/2095682 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Qianzhe Zhu Zhongyang Deng Shirong Zhu Pan Zhao Mingjing Wang Xiaomei Hu |
spellingShingle |
Qianzhe Zhu Zhongyang Deng Shirong Zhu Pan Zhao Mingjing Wang Xiaomei Hu Study on the Clinical Safe and Effective Methods of Arsenic-Containing Compound-Qinghuang Powder in the Treatment of Myelodysplastic Syndrome Evidence-Based Complementary and Alternative Medicine |
author_facet |
Qianzhe Zhu Zhongyang Deng Shirong Zhu Pan Zhao Mingjing Wang Xiaomei Hu |
author_sort |
Qianzhe Zhu |
title |
Study on the Clinical Safe and Effective Methods of Arsenic-Containing Compound-Qinghuang Powder in the Treatment of Myelodysplastic Syndrome |
title_short |
Study on the Clinical Safe and Effective Methods of Arsenic-Containing Compound-Qinghuang Powder in the Treatment of Myelodysplastic Syndrome |
title_full |
Study on the Clinical Safe and Effective Methods of Arsenic-Containing Compound-Qinghuang Powder in the Treatment of Myelodysplastic Syndrome |
title_fullStr |
Study on the Clinical Safe and Effective Methods of Arsenic-Containing Compound-Qinghuang Powder in the Treatment of Myelodysplastic Syndrome |
title_full_unstemmed |
Study on the Clinical Safe and Effective Methods of Arsenic-Containing Compound-Qinghuang Powder in the Treatment of Myelodysplastic Syndrome |
title_sort |
study on the clinical safe and effective methods of arsenic-containing compound-qinghuang powder in the treatment of myelodysplastic syndrome |
publisher |
Hindawi Limited |
series |
Evidence-Based Complementary and Alternative Medicine |
issn |
1741-427X 1741-4288 |
publishDate |
2017-01-01 |
description |
Objective. To establish the clinical safe and effective methods of arsenic-containing compound-Qinghuang Powder (compound-QHP) in the treatment of myelodysplastic syndrome (MDS). Methods. 200 patients with MDS were treated with compound-QHP (daily dose of 0.1 g realgar). The blood arsenic concentrations (BACs) were detected by atomic fluorescence spectrophotometry (HF-AFS). After treatment for 1 month, the patients were randomly divided into group A and group B when the BACs were less than 20 μg/L. Daily dose of realgar was maintained in group A and it was increased to that when the BACs were more than 20 μg/L in group B. The BAC and clinical efficacy and safety in two groups were compared at the end of the treatment with compound-QHP. Results. The average BAC of group B was significantly higher than that of group A (P<0.01). The rates of hematology improvement and reduced transfusion were significantly higher in group B than in group A (P<0.05). The HGB, ANC, and PLT significantly increased in group B after treatment (P>0.05). Conclusions. Monitoring the BAC and adjusting the daily dose of realgar to increase the effective BAC and then improving efficacy without increasing the clinical toxicity are the clinical safe and effective methods in the treatment of MDS. |
url |
http://dx.doi.org/10.1155/2017/2095682 |
work_keys_str_mv |
AT qianzhezhu studyontheclinicalsafeandeffectivemethodsofarseniccontainingcompoundqinghuangpowderinthetreatmentofmyelodysplasticsyndrome AT zhongyangdeng studyontheclinicalsafeandeffectivemethodsofarseniccontainingcompoundqinghuangpowderinthetreatmentofmyelodysplasticsyndrome AT shirongzhu studyontheclinicalsafeandeffectivemethodsofarseniccontainingcompoundqinghuangpowderinthetreatmentofmyelodysplasticsyndrome AT panzhao studyontheclinicalsafeandeffectivemethodsofarseniccontainingcompoundqinghuangpowderinthetreatmentofmyelodysplasticsyndrome AT mingjingwang studyontheclinicalsafeandeffectivemethodsofarseniccontainingcompoundqinghuangpowderinthetreatmentofmyelodysplasticsyndrome AT xiaomeihu studyontheclinicalsafeandeffectivemethodsofarseniccontainingcompoundqinghuangpowderinthetreatmentofmyelodysplasticsyndrome |
_version_ |
1725518017675132928 |